Volume 11 Issue 151
Published - 14:00 UTC 08:00 EST 12-Jun-2009 
Next Update - 14:00 UC 08:00 EST 13-Jun-2009

Editor: Susan K. Boyer, RN
© Vidyya.
All rights reserved.



Combo treatment boosts survival in biliary tract cancers

(12 June 2009: VIDYYA MEDICAL NEWS SERVICE) -- The combination of cisplatin (Platinol) and gemcitabine (Gemzar) helped patients with advanced, inoperable cancers of the biliary tract (gallbladder and bile duct) live several months longer than patients who received gemcitabine alone (11.7 versus 8.2 months), according to findings presented at the ASCO annual meeting. For patients with these rare but difficult-to-treat cancers, the combination therapy will likely become the new standard treatment, the researchers predicted.

“We consider cisplatin and gemcitabine to now be the worldwide standard of care and the backbone for further studies of patients with advanced biliary tract cancers,” lead investigator Dr. Juan Valle of the University of Manchester in the United Kingdom said in a press briefing before the meeting. At the briefing, ASCO President Dr. Richard Schilsky called the study “definitive” and added: “As one who treats these patients in my own clinic, it’s very comforting to have a clear standard of care to offer them.”

The final-stage ABC-02 trial included 410 patients with advanced biliary tract, gallbladder, or ampullary carcinoma. In addition to improving overall survival, the combination therapy delayed the progression of the disease by 2 months (8.5 versus 6.5 months). In both groups, side effects were similar, although there was a slight increase of neutropenia in patients receiving the combination therapy, the researchers said.

The next steps will involve trying to add some of the newer targeted cancer therapies to the combination and identifying which patients will benefit most from these treatments, noted Dr. Valle. He cautioned that adding another chemotherapy drug could increase toxicity without producing a benefit to patients.

Return to Vidyya Medical News Service for 12 June 2009

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.